Q-omics provides the consensus-scored LYVE1 profile across patient tissues and cancer cell-line models. LYVE1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LYVE1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LYVE1 protein abundance shows 30,978 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where LYVE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYVE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYVE1 survival associations across molecular data types. LYVE1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYVE1 RNA expression–survival associations across cancer types. High LYVE1 expression shows unfavorable associations in KIRP, OV, ACC and LUSC, but favorable associations in KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LYVE1 RNA expression.
This table summarizes LYVE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LYVE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYVE1 shows lower tumor expression in COAD, THCA, BLCA, LUAD, KIRP and STAD. The COAD box plot shows higher LYVE1 RNA expression in normal versus tumor tissue (log2 FC = −3.591, t-test p < 0.001).
This table shows molecular features associated with LYVE1 in patient tissues and cancer cell lines. In patient samples, LYVE1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LYVE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
